What titration schedule was used in the retatrutide Phase 2 trial?

In the 12 mg arm, participants started at 2 mg once weekly subcutaneously and escalated through 4 mg and 8 mg to a 12 mg target, with each step at a 4-week interval, so 12 weeks to reach the target. The trial registration describes that arm as receiving a 2 mg starting dose followed by 4 mg, 8 mg and then 12 mg, administered as a subcutaneous injection once weekly (NCT04881760). Published as Jastreboff AM et al., N Engl J Med 2023;389(6):514-526, PMID 37366315.

Was there only one dosing schedule?

No. The trial ran several arms: 1 mg, a 4 mg target reached either directly or from a 2 mg start, an 8 mg target reached from either a 2 mg or a 4 mg start, and the 12 mg arm starting at 2 mg. So the published evidence describes more than one pathway, and the same target dose was reached by different routes in different arms.

Is retatrutide approved, and can these doses be used outside a trial?

No. To our knowledge, as of July 2026, retatrutide holds no marketing authorisation in the EU and no FDA approval for any indication. Eli Lilly states publicly that it is not available for public use and is being studied in clinical trials. The schedules on this page are what the published trials used.

How does the retatrutide schedule compare with semaglutide and tirzepatide?

On paper the shape is similar: all three start low, escalate stepwise and dose once weekly. The intervals differ in how they are specified: semaglutide's label uses 4-week steps, tirzepatide's label says at least 4 weeks, and the retatrutide Phase 2 schedule used 4-week steps. The comparison on this page is a schedule comparison only, drawn from the approved FDA labels for semaglutide (Wegovy) and tirzepatide (Zepbound) alongside a published trial regimen for an investigational compound. It is not an efficacy or safety ranking, and no head-to-head trial of retatrutide against either compound exists.

Why does retatrutide reach 12 mg while semaglutide targets 2.4 mg? Is it a stronger drug?

No, and this is a common misreading. Milligram numbers are not comparable across different molecules: they reflect potency per milligram, molecular weight and formulation, not how powerful a compound is. Comparing 12 mg of one peptide with 2.4 mg of another tells you nothing about their relative effect.

What is known about retatrutide pharmacokinetics?

The Phase 1b multiple-ascending-dose trial in people with type 2 diabetes (Urva S et al., Lancet 2022;400(10366):1869-1881, PMID 36354040) established the pharmacokinetic basis for once-weekly dosing. The compound carries a fatty-acid side chain that binds albumin, which extends its elimination half-life to roughly six days and is what makes a weekly schedule feasible.

Do the published trials say how the vials were formulated or reconstituted?

No. The published reports describe doses and schedules, not the formulation of the investigational product, its concentration or any reconstitution procedure. So if you see a reconstitution recipe attributed to the trial data, it is not from there.

What were the main side effects at these doses?

Gastrointestinal effects dominate and are dose-related: nausea, diarrhoea, vomiting and constipation, mostly mild to moderate in the Phase 2 report. A sensory effect, dysaesthesia, appeared in the later TRIUMPH-4 sponsor topline at 8.8% (9 mg) and 20.9% (12 mg) against 0.7% on placebo. We cover the safety profile in detail in a separate article.

How long did the Phase 2 trial run and how many people took part?

The trial enrolled 338 adults and had a 48-week treatment period. It was a randomised, placebo-controlled Phase 2 trial in obesity, funded by Eli Lilly, registered as NCT04881760 and published in the New England Journal of Medicine in 2023 (PMID 37366315).

What weight changes were reported at each dose?

At 48 weeks the least-squares mean change in body weight was -8.7% at 1 mg, -17.1% in the combined 4 mg group, -22.8% in the combined 8 mg group and -24.2% at 12 mg, against -2.1% on placebo. The dose-response is clear across the arms.

Are the Phase 3 TRIUMPH results published?

The results are not. The TRIUMPH programme's rationale and design were published peer-reviewed (Diabetes Obes Metab 2026, PMID 41090431), but the outcome data so far exists only as sponsor topline announcements. Those figures have not been through journal peer review and remain provisional pending full publication.

Does a longer titration mean fewer side effects?

The published data supports something narrower than that. It shows that a lower starting dose partially mitigated gastrointestinal events at the same target dose. It does not isolate the length or speed of escalation as an independent causal factor, because the trial was not designed to answer that question.

Why is the starting dose 2 mg and not something lower?

The trial tested 2 mg and 4 mg as starting points, and the 2 mg start is the one used for the 12 mg arm. A 1 mg arm existed but as a target dose rather than a starting step. The published data does not test starts below 2 mg, so what a lower start would do is simply unknown from this trial.

Where can I read the primary sources myself?

The Phase 2 obesity trial: Jastreboff AM et al., N Engl J Med 2023;389(6):514-526, PMID 37366315, registered NCT04881760. The Phase 1b pharmacokinetic trial: Urva S et al., Lancet 2022;400(10366):1869-1881, PMID 36354040. The TRIUMPH design paper: PMID 41090431. The comparator schedules come from the FDA prescribing information for Wegovy and Zepbound, both linked in the references below.

Where can I see your certificates of analysis?

They are published on our lab reports page, organised by product and batch, with the testing lab named and a verification link where the lab provides one. Most of those reports were commissioned by the manufacturer rather than by us, and we say so rather than describing them as independent. A certificate reports on the material in a vial and says nothing about the clinical trial data discussed on this page.

Retatrutide Dosing and Titration in Clinical Research

Q: Why did the trial start at a low dose instead of the target dose?

Tolerability is the stated rationale for stepwise escalation across this drug class. What the Phase 2 publication actually establishes is narrower: gastrointestinal events were dose-related and "were partially mitigated with a lower starting dose". So the evidence is about the starting dose, not about how fast you escalate; the trial never compared escalation speeds against each other.

Retatrutidemetabolic

First-ever triple-action weight management peptide targeting three receptors at once: GLP-1, GIP, and glucagon. Shown exceptional results in Phase 2 trials - up to 24% weight reduction. The most advanced metabolic peptide available.

Tirzepatidemetabolic

A first-in-class dual GIP and GLP-1 receptor agonist, and one of the most extensively studied compounds in modern metabolic and weight-regulation research. Supplied as a lyophilised research peptide with a per-batch certificate of analysis, for laboratory and in-vitro use only.

Retatrutide (LY-3437943) is an investigational once-weekly triple-hormone receptor agonist that activates GLP-1, GIP, and glucagon receptors. Published clinical data describe a structured dose-escalation approach used during treatment initiation. This article summarizes dosing and pharmacokinetic points from published retatrutide studies and compares them with the labeled escalation schedules for semaglutide and tirzepatide.

Published Lilly study reports describe investigational clinical-trial use of retatrutide. They do not establish a general reconstitution or storage protocol for third-party lyophilized retail products.

Pharmacokinetics of Retatrutide

Published Phase 1 and Phase 2 studies support once-weekly subcutaneous dosing. Specific pharmacokinetic estimates such as half-life and dose proportionality come from the early multiple-ascending-dose study rather than from the obesity Phase 2 paper.

Parameter	Value	Source
Half-life (t1/2)	Approximately 6 days	Urva et al., Lancet 2022
Route of administration	Subcutaneous injection	Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ
Dosing interval	Once weekly in published Phase 1b and Phase 2 trials	Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ
Exposure	Dose-proportional pharmacokinetics in the Phase 1b study	Urva et al., Lancet 2022

Half-life (t1/2)

Value: Approximately 6 days
Source: Urva et al., Lancet 2022

Route of administration

Value: Subcutaneous injection
Source: Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ

Dosing interval

Value: Once weekly in published Phase 1b and Phase 2 trials
Source: Urva et al., Lancet 2022; Jastreboff et al., NEJM 2023; Lilly FAQ

Exposure

Value: Dose-proportional pharmacokinetics in the Phase 1b study
Source: Urva et al., Lancet 2022

The approximately 6-day half-life is consistent with a weekly schedule. The obesity Phase 2 trial then applied 4-week intervals between escalation steps, but that trial should be cited for the schedule itself rather than as the primary source of the pharmacokinetic estimates above.

Titration Schedule from Published Clinical Trials

The randomized Phase 2 obesity trial (Jastreboff AM et al., N Engl J Med 2023, PMID 37366315, registered as NCT04881760) reported several dose groups. In the 12 mg arm, participants followed a stepwise escalation schedule:

Starting dose: 2 mg once weekly
Escalation: higher doses introduced at 4-week intervals
Target dose: 12 mg once weekly

This schedule was used in a clinical trial setting. In the Phase 2 report, gastrointestinal adverse events were dose-related and were partially mitigated by a lower starting dose.

Dosing Table: Week-by-Week Overview

The table below reflects the escalation pattern reported for the 12 mg regimen in the Phase 2 trial (NCT04881760). The trial registration describes that arm verbatim as: "Participants received 2 mg LY3437943 starting dose followed by 4 mg LY3437943, 8 mg LY3437943 and then 12 mg LY3437943 administered as SC injection QW." Escalation ran every 4 weeks for up to 12 weeks.

Week	Dose (s.c., once weekly)	Phase	Notes
1	2 mg	Starting dose	Treatment initiation
2	2 mg	Starting dose
3	2 mg	Starting dose
4	2 mg	Starting dose	End of first 4-week interval
5	4 mg	Escalation 1	First dose increase
6	4 mg	Escalation 1
7	4 mg	Escalation 1
8	4 mg	Escalation 1	End of second 4-week interval
9	8 mg	Escalation 2	Second dose increase
10	8 mg	Escalation 2
11	8 mg	Escalation 2
12	8 mg	Escalation 2	End of third 4-week interval
13+	12 mg	Maintenance dose	Assigned target dose

Dose (s.c., once weekly): 2 mg
Phase: Starting dose
Notes: Treatment initiation

Dose (s.c., once weekly): 2 mg
Phase: Starting dose
Notes

Dose (s.c., once weekly): 2 mg
Phase: Starting dose
Notes

Dose (s.c., once weekly): 2 mg
Phase: Starting dose
Notes: End of first 4-week interval

Dose (s.c., once weekly): 4 mg
Phase: Escalation 1
Notes: First dose increase

Dose (s.c., once weekly): 4 mg
Phase: Escalation 1
Notes

Dose (s.c., once weekly): 4 mg
Phase: Escalation 1
Notes

Dose (s.c., once weekly): 4 mg
Phase: Escalation 1
Notes: End of second 4-week interval

Dose (s.c., once weekly): 8 mg
Phase: Escalation 2
Notes: Second dose increase

Dose (s.c., once weekly): 8 mg
Phase: Escalation 2
Notes

Dose (s.c., once weekly): 8 mg
Phase: Escalation 2
Notes

Dose (s.c., once weekly): 8 mg
Phase: Escalation 2
Notes: End of third 4-week interval

13+

Dose (s.c., once weekly): 12 mg
Phase: Maintenance dose
Notes: Assigned target dose

Total titration duration to 12 mg: 12 weeks.

The same trial also studied lower target doses. The published evidence therefore supports more than one retatrutide dosing pathway, depending on the study arm.

Starting Dose and Tolerability

The published retatrutide studies, like the approved semaglutide and tirzepatide labels, use gradual escalation rather than immediate full-dose exposure. Tolerability is the stated rationale. Be precise about what the data shows here: the Phase 2 publication reports that gastrointestinal events were dose-related and "were partially mitigated with a lower starting dose". The trial did not compare escalation speeds against each other, so the independent effect of how fast you escalate was never tested.

Gastrointestinal Tolerability

In the Phase 2 trial, the most commonly reported adverse events were gastrointestinal, including:

nausea
diarrhea
vomiting
constipation

In the published Phase 2 abstract, these events were described as dose-related, mostly mild to moderate, and partially mitigated with a lower starting dose. This article does not repeat exact event percentages because those figures depend on the analysis population, dose arm, and time window used in the source publication.

Mechanistic Context

Retatrutide engages three metabolic signalling pathways, one more than tirzepatide and two more than semaglutide. That is a mechanistic difference, and it does not by itself establish anything about tolerability. What is documented is simply the design: the Phase 2 trial used gradual up-titration rather than immediate exposure to the highest dose.

Comparison of Dosing Schedules: Semaglutide, Tirzepatide, Retatrutide

The comparison below places approved product labels alongside an investigational clinical-trial regimen:

semaglutide and tirzepatide rows summarize current FDA-labeled escalation schedules for approved products
retatrutide summarizes the published clinical-trial schedule for an investigational drug

Parameter	Semaglutide (Wegovy injection)	Tirzepatide (Zepbound)	Retatrutide
Development status	FDA-approved product	FDA-approved product	Investigational drug
Receptors	GLP-1	GLP-1 + GIP	GLP-1 + GIP + glucagon
Starting dose	0.25 mg	2.5 mg	2 mg
Illustrative target dose	2.4 mg	15 mg	12 mg in one Phase 2 arm
Titration steps	0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg	2.5 -> 5 -> 7.5 -> 10 -> 12.5 -> 15 mg	2 -> 4 -> 8 -> 12 mg
Interval per step	4 weeks	At least 4 weeks	4 weeks in the published Phase 2 schedule
Dosing interval	Once weekly	Once weekly	Once weekly

Development status

Semaglutide (Wegovy injection): FDA-approved product
Tirzepatide (Zepbound): FDA-approved product
Retatrutide: Investigational drug

Receptors

Semaglutide (Wegovy injection): GLP-1
Tirzepatide (Zepbound): GLP-1 + GIP
Retatrutide: GLP-1 + GIP + glucagon

Starting dose

Semaglutide (Wegovy injection): 0.25 mg
Tirzepatide (Zepbound): 2.5 mg
Retatrutide: 2 mg

Illustrative target dose

Semaglutide (Wegovy injection): 2.4 mg
Tirzepatide (Zepbound): 15 mg
Retatrutide: 12 mg in one Phase 2 arm

Titration steps

Semaglutide (Wegovy injection): 0.25 -> 0.5 -> 1.0 -> 1.7 -> 2.4 mg
Tirzepatide (Zepbound): 2.5 -> 5 -> 7.5 -> 10 -> 12.5 -> 15 mg
Retatrutide: 2 -> 4 -> 8 -> 12 mg

Interval per step

Semaglutide (Wegovy injection): 4 weeks
Tirzepatide (Zepbound): At least 4 weeks
Retatrutide: 4 weeks in the published Phase 2 schedule

Dosing interval

Semaglutide (Wegovy injection): Once weekly
Tirzepatide (Zepbound): Once weekly
Retatrutide: Once weekly

This table should not be read as a head-to-head efficacy ranking. It is a schedule comparison only. Retatrutide also remains investigational. Lilly's public FAQ states that retatrutide is not available for public use and is being studied in Phase 3 clinical trials.

Formulation and Reconstitution: What the Published Trial Data Do Not Show

The available retatrutide clinical publications do not provide a generalizable protocol for reconstituting retail lyophilized vials with bacteriostatic water. That distinction matters because:

Lilly describes retatrutide as an investigational drug available through its clinical development program, not as an approved commercial product
the published trial reports summarize dosing and outcomes, but do not establish a standard compounding or handling method for third-party products
product-specific concentration, excipients, sterility controls, and storage instructions can differ across suppliers

For that reason, a research article grounded in published trial evidence should not present a bacteriostatic-water reconstitution table as though it were part of Lilly's clinical protocol.

Storage and Handling Caveat

The same limitation applies to storage claims. The published clinical-trial sources cited here do not provide a general storage standard for commercially sold reconstituted retatrutide vials. Any handling or storage instructions should come from product-specific manufacturer documentation and laboratory SOPs, not from inference based on Lilly trial publications.

Scope of the Published Evidence

The published retatrutide sources cited here support three narrow points relevant to dosing:

published clinical studies used once-weekly subcutaneous administration
the Phase 2 obesity trial used stepwise escalation to the assigned target dose
the clinical publications do not provide a general protocol for third-party vial reconstitution, storage, or supply planning

Broader operational details should come from study-specific documents, manufacturer materials, and institutional procedures rather than from inference based on the published trial papers alone.

Conclusion

The published retatrutide evidence supports a once-weekly, stepwise escalation approach in clinical research, with the 12 mg Phase 2 regimen moving from 2 mg to 4 mg to 8 mg to 12 mg at 4-week intervals. The available sources also support cautious language: retatrutide remains investigational, and published Lilly trial reports do not provide a standard reconstitution or storage protocol for third-party commercial vials.

For schedule comparisons across the incretin field, approved product labels and investigational trial regimens should be cited separately and interpreted on their own terms.

-> Research Product: Retatrutide

This article is intended solely for informational purposes in scientific research. It does not provide medical advice and does not describe an approved prescribing protocol.

Frequently Asked Questions

References

Urva S, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869-1881. PMID 36354040.
Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315. ClinicalTrials.gov NCT04881760.
Eli Lilly and Company. What to know about retatrutide.
U.S. FDA. Wegovy prescribing information.
U.S. FDA. Zepbound prescribing information.

Disclaimer: FOR RESEARCH USE ONLY. All products from PeptidesDirect are intended exclusively for in-vitro research and laboratory use. Not for human consumption. Not for in-vivo applications. By purchasing, you confirm that the products are not intended for ingestion or any other application in humans.